MedTrace Logo

Combination Hormone Therapy Followed by Radiation Therapy in Treating Patients With Prostate Cancer

NCT00003734 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 276

Last updated 2016-07-21

No results posted yet for this study

Summary

RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using triptorelin and flutamide may fight cancer by reducing the production of androgens. It is not yet known whether giving hormone therapy for 4 months is more effective than giving therapy for 8 months prior to radiation therapy for prostate cancer.

PURPOSE: Randomized phase III trial to study the effectiveness of combination hormone therapy for 4 or 8 months followed by radiation therapy in treating patients with prostate cancer.

Conditions

Interventions

DRUG

flutamide

DRUG

triptorelin

RADIATION

radiation therapy

Sponsors & Collaborators

  • St. Luke's Hospital, Ireland

    lead OTHER

Principal Investigators

  • John Gerard Armstrong, MD, MB, MRCPI · Saint Luke's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-12-31

Countries

  • Ireland
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003734 on ClinicalTrials.gov